Cargando…
Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
Obesity and Type 2 diabetes represent global health challenges, and there is an unmet need for long-lasting and effective pharmacotherapies. Although long-acting glucagon-like peptide-1 (GLP-1) analogues are now in routine use for diabetes and are now being utilised for obesity per se, the need for...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457634/ https://www.ncbi.nlm.nih.gov/pubmed/34566894 http://dx.doi.org/10.3389/fendo.2021.735019 |